GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models

by barry-jtcir | Aug 7, 2023 | Press Releases

Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment of systemic lupus erythematosus (SLE) Company expects to commence Phase 1a/b...

GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference

by barry-jtcir | Aug 3, 2023 | Press Releases

– Live moderated webcast fireside chat today, August 3rd at 11:15 AM ET LA JOLLA, CA, Aug. 03, 2023 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural...

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event

by barry-jtcir | Jul 24, 2023 | Press Releases

– Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...

GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series

by barry-jtcir | Jul 5, 2023 | Press Releases

– Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing...

GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio

by barry-jtcir | Jun 27, 2023 | Press Releases

– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) – Company building a robust global patent estate LA JOLLA, CA, June 27, 2023 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI...